ACAD
29.27
+1.05
+3.72%
AEMD
2.3
+0.25
+12.20%
APRI
1.01
-0.02
-1.94%
ARNA
16.6
+0.85
+5.40%
ATEC
1.86
+0.05
+2.76%
CNAT
5.11
+0.19
+3.86%
CRXM
0.175
+0.013
+7.9827%
CYTX
1.01
-0.02
-1.94%
DXCM
78.33
+0.49
+0.63%
GNMK
12.39
+0.18
+1.47%
HALO
14.59
+0.27
+1.89%
ILMN
177.38
+2.08
+1.19%
INNV
0.11
0.00
+4.27%
INO
8.06
+0.09
+1.13%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
120.2
+4.49
+3.88%
LPTN
2.93
0.00
0.00%
MBVX
1.42
-0.03
-2.0621%
MEIP
2.13
+0.04
+1.91%
MNOV
5.47
+0.08
+1.48%
MRTX
3.85
+0.3
+8.45%
MSTX
0.131
0.00
0.00%
NBIX
47.47
+1.8
+3.94%
NUVA
76.83
-0.72
-0.93%
ONCS
1.16
+0.07
+6.42%
ONVO
2.67
+0.01
+0.38%
OREX
2.99
+0.02
+0.67%
OTIC
17.5
+1.45
+9.03%
QDEL
25.98
+0.17
+0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.949
+0.004
+0.4232%
RMD
78.39
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.05
+0.01
+0.49%
SRNE
1.9
+0.15
+8.57%
TROV
0.946
+0.047
+5.2374%
VICL
2.47
+0.05
+2.07%
VOLC
18
0.00
0.00%
ZGNX
15
+0.25
+1.69%
ACAD
29.27
+1.05
+3.72%
AEMD
2.3
+0.25
+12.20%
APRI
1.01
-0.02
-1.94%
ARNA
16.6
+0.85
+5.40%
ATEC
1.86
+0.05
+2.76%
CNAT
5.11
+0.19
+3.86%
CRXM
0.175
+0.013
+7.9827%
CYTX
1.01
-0.02
-1.94%
DXCM
78.33
+0.49
+0.63%
GNMK
12.39
+0.18
+1.47%
HALO
14.59
+0.27
+1.89%
ILMN
177.38
+2.08
+1.19%
INNV
0.11
0.00
+4.27%
INO
8.06
+0.09
+1.13%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
120.2
+4.49
+3.88%
LPTN
2.93
0.00
0.00%
MBVX
1.42
-0.03
-2.0621%
MEIP
2.13
+0.04
+1.91%
MNOV
5.47
+0.08
+1.48%
MRTX
3.85
+0.3
+8.45%
MSTX
0.131
0.00
0.00%
NBIX
47.47
+1.8
+3.94%
NUVA
76.83
-0.72
-0.93%
ONCS
1.16
+0.07
+6.42%
ONVO
2.67
+0.01
+0.38%
OREX
2.99
+0.02
+0.67%
OTIC
17.5
+1.45
+9.03%
QDEL
25.98
+0.17
+0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.949
+0.004
+0.4232%
RMD
78.39
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.05
+0.01
+0.49%
SRNE
1.9
+0.15
+8.57%
TROV
0.946
+0.047
+5.2374%
VICL
2.47
+0.05
+2.07%
VOLC
18
0.00
0.00%
ZGNX
15
+0.25
+1.69%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.

Be Sociable, Share!